ART reports $2.9 million cash infusion to prepare its First-in-Human study

PARIS, April 4, 2012—Arterial Remodeling Technologies (“ART”) reported today that in vivo data strongly suggest that its next-generation bioresorbable stent promotes positive arterial remodeling in a post-angioplasty porcine model at six months follow-up. In addition, acute safety data are promising: there have been more than 300 MACE-free consecutive implantations of its bioresorbable stent in its preclinical phase of development.

 

ART-News 120404